Literature DB >> 18399875

Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis.

Kazue Higuchi1, Nobuyuki Harada, Toru Mori.   

Abstract

BACKGROUND AND
OBJECTIVE: Chemotherapy for Mycobacterium tuberculosis infection may decrease interferon (IFN)-gamma responses to early secretory antigenic target 6 and culture filtrate protein (CFP)-10; a reaction that could be useful to monitor the success of treatment. We investigated IFN-gamma responses in subjects with latent TB infection before and after isoniazid (INH) chemotherapy.
METHODS: A total of 48 patients who had contact with a TB patient in a psychiatric hospital were suspected to have latent TB infection on the basis of a positive QuantiFERON-TB Gold (QFT-G) test and were offered INH treatment for 6 months. After INH chemotherapy, IFN-gamma responses were again quantified and compared with initial measurements.
RESULTS: Thirty-four patients completed 6 months of therapy and 28 were retested. Seven (25%) had a negative test and the other patients showed an overall decline. Geometric mean for early secretory antigenic target 6 decreased from 1.398 to 0.362 (P < 0.001), and that for CFP-10 from 0.312 to 0.120 (P < 0.001). A subsequent QFT-G test carried out 18 months after chemotherapy showed no further decline of IFN-gamma responses.
CONCLUSIONS: If the success of chemotherapy is defined as negative conversion in the QFT-G test, these results suggest that although the waning of QFT-G responses as a result of chemotherapy is an important characteristic of IFN-gamma responses, the extent of waning would not be sufficient to allow effective monitoring of the success of chemotherapy because a majority of contacts still showed positive responses in the QFT-G test even after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18399875     DOI: 10.1111/j.1440-1843.2008.01244.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  25 in total

1.  Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4+ T cells.

Authors:  Ilaria Sauzullo; Fabio Mengoni; Claudia Mascia; Raffaella Rossi; Miriam Lichtner; Vincenzo Vullo; Claudio M Mastroianni
Journal:  Med Microbiol Immunol       Date:  2015-06-25       Impact factor: 3.402

Review 2.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

Review 3.  The immunology of tuberculosis: from bench to bedside.

Authors:  Keertan Dheda; Stephan K Schwander; Bingdong Zhu; Richard N van Zyl-Smit; Ying Zhang
Journal:  Respirology       Date:  2010-04       Impact factor: 6.424

4.  Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results.

Authors:  Nira R Pollock; Suely S Kashino; Danielle R Napolitano; Alex Sloutsky; Swati Joshi; Jasmine Guillet; Michael Wong; Edward Nardell; Antonio Campos-Neto
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

5.  Reversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected children.

Authors:  Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley
Journal:  BMC Infect Dis       Date:  2010-05-27       Impact factor: 3.090

6.  Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country.

Authors:  Anne M Dyrhol-Riise; Gerd Gran; Tore Wentzel-Larsen; Bjørn Blomberg; Christel Gill Haanshuus; Odd Mørkve
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

7.  Short-term reproducibility of a commercial interferon gamma release assay.

Authors:  A K Detjen; L Loebenberg; H M S Grewal; K Stanley; A Gutschmidt; C Kruger; N Du Plessis; M Kidd; N Beyers; G Walzl; A C Hesseling
Journal:  Clin Vaccine Immunol       Date:  2009-06-17

Review 8.  The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.

Authors:  Rossana Scrivo; Ilaria Sauzullo; Fabio Mengoni; Valeria Riccieri; Alfonso Maria Altieri; Laura Cantoro; Vincenzo Vullo; Claudio Maria Mastroianni; Guido Valesini
Journal:  Clin Rheumatol       Date:  2014-05-15       Impact factor: 2.980

9.  Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort.

Authors:  S W Lee; S H Lee; J-J Yim
Journal:  Infection       Date:  2012-05-15       Impact factor: 3.553

Review 10.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.

Authors:  Clifton E Barry; Helena I Boshoff; Véronique Dartois; Thomas Dick; Sabine Ehrt; JoAnne Flynn; Dirk Schnappinger; Robert J Wilkinson; Douglas Young
Journal:  Nat Rev Microbiol       Date:  2009-10-26       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.